ORPHA:424039
Squamous cell carcinoma of pancreas
Also known as: Pancreatic squamous cell carcinoma
Publications
295
66.3th percentile
Trials
3
Interventional, condition-specific
Researchers
1,283
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare epithelial tumor of the exocrine pancreas, histologically characterized by presence of keratinization and/or intracellular bridges and lymphovascular and perineural invasion, as well as high metastatic potential. Patients present with upper abdominal and back pain, anorexia, weight loss, nausea, vomiting and jaundice.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018521
- UMLS:C2675993
- NCIT:C173813
Additional Mondo synonyms (2)
pancreas squamous cell carcinoma · pancreatic squamous cell carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
295 matched papers (179 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
3 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
295
295 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
295 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
179 in the last 10 years · medium confidence · 66.3th percentile (publications denominator)
Phrase hits: 295 · MeSH hits: 0
Who's working on it?
1,283
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang J5 papers · 2026
Department of General Surgery Second Affiliated Hospital of Nanchang University, Nanchang, China.
Papers in Europe PMC - 02Huang Z4 papers · 2023
Department of Otolaryngology-Head and Neck Surgery, Key Laboratory of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730 China.
Papers in Europe PMC - 03Liu Z4 papers · 2026
Queen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Papers in Europe PMC - 04Wang Y4 papers · 2025
Department of Medicine, Burning Rock Biotech, Guangzhou, China.
Papers in Europe PMC - 05Zhang J4 papers · 2025
Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Papers in Europe PMC - 06Zhou Y4 papers · 2025
Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 07Li J3 papers · 2025
Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Papers in Europe PMC - 08Li W3 papers · 2024
Department of Gastroenterology, Changhai hospital, Naval Medical University, Shanghai 200433, China.
Papers in Europe PMC - 09Li X3 papers · 2024
Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Papers in Europe PMC - 10Liu J3 papers · 2023
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 270 Dong'An Road, Shanghai 200032, P R China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P R China; Shanghai Pancreatic Cancer Institute, Shanghai 200032, P R China; Pancreatic Cancer Institute, Fudan University, Shanghai 200032, P R China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
3
interventional trials for this specific condition
3 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 2,553 trials are registered for squamous cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
3 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 86.7th percentile).
medium confidence · 86.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
3 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04858334·RECRUITING·APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Not reviewed·Conditions: Pancreatic Acinar Cell Carcinoma · Pancreatic Adenosquamous Carcinoma · Pancreatic Squamous Cell Carcinoma · Resectable Pancreatic Acinar Cell Carcinoma·Matched via name phrase
Broader category: squamous cell carcinoma
2,553
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06662058·RECRUITING·Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Cutaneous Squamous Cell Carcinoma of the Head and Neck · Head and Neck Carcinoma of Unknown Primary · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06540443·RECRUITING·Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Lymph Node Metastasis·Matched via name phrase
- NCT06599775·NOT YET RECRUITING·Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Not reviewed·Conditions: Resectable Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT07173270·NOT YET RECRUITING·Improved Oral Health in Head and Neck Cancer Survivors
Not reviewed·Conditions: Head and Neck Cancer Squamous Cell Carcinoma · Head and Neck Cancer·Matched via name phrase
- NCT07487896·RECRUITING·A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Not reviewed·Conditions: Advanced Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06659146·RECRUITING·Thermotherapy in Addition to SOC Palliative Radiotherapy
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma · Breast Cancer Recurrent·Matched via name phrase
- NCT07726199·RECRUITING·Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread
Not reviewed·Conditions: Oral Squamous Cell Carcinoma (OSCC)·Matched via name phrase
- NCT06589609·RECRUITING·Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Not reviewed·Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC)·Matched via name phrase
- NCT06161532·RECRUITING·Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Not reviewed·Conditions: Small Cell Carcinoma of the Bladder · Small Cell Carcinoma of the Urinary Tract · Squamous Cell Carcinoma of the Bladder · Squamous Cell Carcinoma of the Urinary Tract·Matched via name phrase
- NCT06915454·RECRUITING·High-Resolution PET-CT Imaging for Surgical Margin Visualization
Not reviewed·Conditions: Cancer · Solid Malignant Tumors · SCC - Squamous Cell Carcinoma · HNSCC·Matched via name phrase
- NCT06693323·RECRUITING·Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
Not reviewed·Conditions: HNSCC · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07629817·NOT YET RECRUITING·Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06648096·RECRUITING·Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Not reviewed·Conditions: Fanconi Anemia · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07392580·RECRUITING·Intralesional Chemotherapy (IC): Cisplatin + Epinephrine
Not reviewed·Conditions: Laryngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT05747625·RECRUITING·(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Squamous Cell Carcinoma · Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 17 · after dedupe 17 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 17 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (17)
- isrctn·ISRCTN78284158·No longer recruiting·Heated intraperitoneal chemotherapy for the treatment of primary ovarian cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN76893830·No longer recruiting·Is it safe to stop insulin injections in older adults with type 2 diabetes?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10010669·No longer recruiting·A study to assess the effect of tiragolumab in presence of atezolizumab and bevacizumab in participants detected with lung cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11595117·No longer recruiting·A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN91431511·No longer recruiting·Does screening with the Galleri test in the NHS reduce the likelihood of a late-stage cancer diagnosis?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11503604·Recruiting·A Phase II clinical trial to compare the effectiveness of gemcitabine and nab-paclitaxel administered in combination with ATRA vs without ATRA in patients with locally advanced treatment-naïve pancreatic cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17354232·No longer recruiting·A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17282276·No longer recruiting·The efficacy of epirubicin, cisplatin and capecitabine in carcinomas of unknown primary origin (CUP): prospective validation of diagnosis, classfication and metabolic responses
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN44138942·No longer recruiting·Comparative Pancreas Induction Study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62918594·No longer recruiting·A Phase I/IIa trial of HMBD-001 in advanced HER3-positive solid tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN84044406·No longer recruiting·A Phase I trial of LY3143921 hydrate in solid tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26628699·Recruiting·A Phase I/II trial of UCB4594 in participants with advanced cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN34023049·No longer recruiting·Comparison of organs at risk and target volumes using MRI and CT scan in head and neck malignancy radiation treatment planning
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10978180·Stopped·A Phase 1b/IIa trial to explore the combination of a new drug, PLX-7486, with gemcitabine in patients with advanced cancer (part 1b) and with advanced pancreatic ductal cancer and cancer-related pain (Part IIa)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN76291951·No longer recruiting·WISTERIA: WEE1 inhibitor with cisplatin and radiotherapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN02750650·No longer recruiting·Health benefits of a novel exercise intervention in Type 2 diabetes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18563749·No longer recruiting·A phase II study of Gemcitabine and Bexarotene (GemBex) in the treatment of cutaneous T-cell lymphoma
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Squamous cell carcinoma of pancreas — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Squamous cell carcinoma of pancreas" OR "Squamous cell carcinoma of the pancreas" OR "Pancreatic squamous cell carcinoma" OR "pancreas squamous cell carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Squamous cell carcinoma of pancreas" OR "Squamous cell carcinoma of the pancreas" OR "Pancreatic squamous cell carcinoma" OR "pancreas squamous cell carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 3 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"squamous cell carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (295) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium
Ingested 2026-07-27T15:55:32.466Z
